Celldex Therapeutics (NASDAQ:CLDX) : 8 Wall Street analysts covering Celldex Therapeutics (NASDAQ:CLDX) believe that the average level the stock could reach for the short term is $8.63. The maximum price target given is $24 and the minimum target for short term is around $3, hence the standard deviation is calculated at $6.89.
Other Equity analysts have also commented on the company shares. Equity Analysts at the Jefferies downgrades the rating on Celldex Therapeutics (NASDAQ:CLDX). The brokerage firm has issued a Hold rating on the shares. The shares were previously rated Buy. The Analysts at the ratings agency lowers the price target from $31 per share to $4 per share. The rating by the firm was issued on March 8, 2016.
Celldex Therapeutics (NASDAQ:CLDX): stock turned positive on Thursday. Though the stock opened at $4.52, the bulls momentum made the stock top out at $4.58 level for the day. The stock recorded a low of $4.41 and closed the trading day at $4.57, in the green by 2.70%. The total traded volume for the day was 2,202,495. The stock had closed at $4.45 in the previous days trading.
The company shares have dropped -82.50% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $28.08 and the one year low was seen on Mar 17, 2016. The 50-Day Moving Average price is $4.16 and the 200 Day Moving Average price is recorded at $7.15. On the companys insider trading activities, The Securities and Exchange Commission has divulged that Catlin Avery W, officer (Sr. VP & CFO) of Celldex Therapeutics, Inc., had unloaded 25,000 shares at an average price of $18 in a transaction dated on November 23, 2015. The total value of the transaction was worth $450,000.
Celldex Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development, includes varlilumab also referred to as CDX-1127, a fully human therapeutic monoclonal antibody for cancer indications, CDX-1401, a targeted immunotherapeutic for cancer indications and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.